Navigation Links
Nile Therapeutics Receives Positive NASDAQ Panel Decision
Date:3/2/2011

tide, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Nile's ability to regain compliance with NASDAQ's listing requirements are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place undue reliance on Nile's forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements Nile makes. Various important factors that could cause actual results or events to differ materially from the forward-looking statements that Nile makes include whether the price of Nile's common stock will close at or above $1.00 for at least 10 consecutive business days prior to May 31, 2011, Nile's need to raise additional capital to fund its product development programs to completion, Nile's reliance on third-party researchers to develop its product candidates, and its lack of experience in developing and commercializing pharmaceutical products. Additional risks are described in greater detail in the reports Nile files with the Securities and Exchange Commission, including those described under the caption "Risk Factors" in Item 1A of its Annual Report on Form 10-K for the year ended December 31, 2009 filed with the Securities and Exchange Commission on March 3, 2010. Nile is providing this information as of the dat
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/3/2015)... -- Varian Medical Systems (NYSE: VAR ), world leader in ... in the Middle East with the ... Arabia . Varian Medical Systems Arabia, the result of ... launched today at a ceremony attended by local dignitaries and ... move represents the next step in our commitment both to ...
(Date:6/3/2015)... South 2015 came to a successful conclusion on April 21. ... has been recognized by industry insiders through its professional and ... medical device manufacturing industry in Southern China ... successful return of the MEDTEC brand to Shenzhen ... 2005. , The most ...
(Date:6/3/2015)... 3, 2015  NxStage Medical, Inc. (Nasdaq: NXTM ... , today announced data that home hemodialysis can ... gallons of water annually by transitioning just 20 ... hemodialysis with the NxStage® System One™.  Industry data ... of water per patient per week, whereas home ...
Breaking Medicine Technology:Varian Establishes Local Entity in Saudi Arabia to Support Expansion in Middle East 2MEDTEC Successfully Returns to Southern China 2MEDTEC Successfully Returns to Southern China 3Home Hemodialysis With NxStage System One Can Save California 221 Million Gallons of Water Annually 2
... SETAUKET, N.Y., Aug. 8 Lixte,Biotechnology Holdings, Inc. ... from each of two different types of drugs ... brain cancers have,activity against human pancreatic cancers in ... President and CEO of Lixte, said, "Lixte previously,reported ...
... Bile Acid-Derived Small Molecules ... Diseases, NEW YORK, Aug. 7 Historically, ... that regulate the absorption of,dietary lipids and cholesterol ... acids have broader systemic endocrine,functions, acting as important ...
Cached Medicine Technology:Lixte Biotechnology Holdings Announces That Novel Compounds Being Developed as Potential Treatments for Brain Tumors Have Positive Activity in a Mouse Model of Human Pancreatic Cancer 2Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling 2Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling 3
(Date:6/3/2015)... 2015 The panel of independent experts ... 98 candidates short-listed for the awards presented tonight at ... was fierce but the best-of-the-best can now be revealed ... Group , Volvo swept rivals aside by taking the ... unanimous praise from our panel of expert judges., Stand ...
(Date:6/3/2015)... PA (PRWEB) June 03, 2015 Sitting ... can cause discomfort in the back, neck, shoulders and/or ... other musculoskeletal injuries. In addition, recent research links sitting ... number of chronic diseases. Fortunately, three inventors from Oakville, ... sit at a desk. , They have developed a ...
(Date:6/3/2015)... NY (PRWEB) June 03, 2015 Acne is ... (“bacne”) can be particularly stubborn to eliminate and hard to ... most common in teens and young adults, in the years ... produce sebum, or oil,” says Jayme Bashian, director and lead ... characteristic pimples, blackheads and cysts of acne are caused by ...
(Date:6/3/2015)... These are challenging and unpredictable times for traditional organizations ... business are rewriting the rules for business as we ... traditional businesses to take on a more agile approach ... On top of this there is a growing ... bring new innovation and approaches to business. , The ...
(Date:6/3/2015)... “ Scanalytics ” was featured on NewsWatch as ... latest and coolest technology products available to consumers. Andrew ... conducted the review and shared with viewers how this ... stores. , Tracking statistics in business is invaluable in ... retail this goes a step beyond revenue statistics and ...
Breaking Medicine News(10 mins):Health News:TU-Automotive Awards 2015 winners revealed 2Health News:TU-Automotive Awards 2015 winners revealed 3Health News:Adjustable Height Tabletop Unit Invented by Three InventHelp® Clients (TOR-9278) 2Health News:Back Acne: Tips for Clearer Summer Skin 2Health News:Back Acne: Tips for Clearer Summer Skin 3Health News:Chief Digital Officer of Travelex joins Bayer, Abellio and Just Eat at The Open Mobile Summit London 2Health News:Technology to Analyze Foot Traffic in Retail Stores was featured on NewsWatch Television 2
... benefits of short-term use of hormone therapy in menopausal women ... of life, but they may also shorten their life expectancy ... not to use hormone therapy can be a difficult decision. ... but are the risks worth the benefits? Question researchers . ...
... awareness is needed about the risks of certain prescribed drugs ... // multiple chronic conditions and take several drugs concurrently many ... ,Researchers conducted a study to look at medication prescriptions ... more than 20 percent of the people filled a prescription ...
... with hemophilia arthropathy, a severe form of hemophilia that ... // than other children for developing osteoporosis in ... in preventing osteoporosis from hitting these children, say researchers. ... activities than was previously advised by doctors. An exercise ...
... a tracheoesophageal puncture (TEP), is an incision between the ... small plastic //or silicone valve , researchers say this ... and neck cancer patients who have had their voice ... combined with post operative speech rehabilitation therapy, can provide ...
... have now found a way to genetically engineer the common ... healthy ones intact.// They did this by modifying one gene, ... had to boost the activity of another gene to ensure ... say, “When the virus infects cells, it takes the altered ...
... get a prescription for a potentially lifesaving drug after ... which the heart has trouble pumping blood. // ... who don’t receive an angiotensin-converting enzyme inhibitor are 14-percent ... who do get the drug. ACE inhibitors work by ...
Cached Medicine News:
4 mm x 9 mm tip....
Large. Double-ended. 3 mm pointed end and 5 mm angled end....
4 mm wide tip....
Double-ended. Blunt and semi sharp 5 mm tips. Designated most popular model or size....
Medicine Products: